Reply to Roberto Iacovelli, Walter Artibani, and Giampaolo Tortora's Letter to the Editor re: Ian D. Davis, Wanling Xie, Carmel Pezaro, et al. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol 2017;71:970–8

Ian D. Davis; Carmel Pezaro; Wanling Xie; Toni K. Choueiri; Daniel Y C Heng

doi:10.1016/j.eururo.2016.12.013

Reply to Roberto Iacovelli, Walter Artibani, and Giampaolo Tortora's Letter to the Editor re: Ian D. Davis, Wanling Xie, Carmel Pezaro, et al. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol 2017;71:970–8

Ian D. Davis, Carmel Pezaro, Wanling Xie, Toni K. Choueiri, Daniel Y C Heng

Eastern Health Clinical School

Research output: Contribution to journal › Letter › Other › peer-review

Original language	English
Pages (from-to)	e177-e178
Journal	European Urology
Volume	71
Issue number	6
DOIs	https://doi.org/10.1016/j.eururo.2016.12.013
Publication status	Published - 1 Jun 2017

Access to Document

10.1016/j.eururo.2016.12.013

Cite this

Davis, I. D., Pezaro, C., Xie, W., Choueiri, T. K., & Heng, D. Y. C. (2017). Reply to Roberto Iacovelli, Walter Artibani, and Giampaolo Tortora's Letter to the Editor re: Ian D. Davis, Wanling Xie, Carmel Pezaro, et al. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol 2017;71:970–8. European Urology, 71(6), e177-e178. https://doi.org/10.1016/j.eururo.2016.12.013

Davis, Ian D. ; Pezaro, Carmel ; Xie, Wanling et al. / Reply to Roberto Iacovelli, Walter Artibani, and Giampaolo Tortora's Letter to the Editor re : Ian D. Davis, Wanling Xie, Carmel Pezaro, et al. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol 2017;71:970–8. In: European Urology. 2017 ; Vol. 71, No. 6. pp. e177-e178.

@article{8b218904b5784cd281eb4c62ba8ba847,

title = "Reply to Roberto Iacovelli, Walter Artibani, and Giampaolo Tortora's Letter to the Editor re: Ian D. Davis, Wanling Xie, Carmel Pezaro, et al. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol 2017;71:970–8",

author = "Davis, {Ian D.} and Carmel Pezaro and Wanling Xie and Choueiri, {Toni K.} and Heng, {Daniel Y C}",

year = "2017",

month = jun,

day = "1",

doi = "10.1016/j.eururo.2016.12.013",

language = "English",

volume = "71",

pages = "e177--e178",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier BV",

number = "6",

}

Davis, ID, Pezaro, C, Xie, W, Choueiri, TK & Heng, DYC 2017, 'Reply to Roberto Iacovelli, Walter Artibani, and Giampaolo Tortora's Letter to the Editor re: Ian D. Davis, Wanling Xie, Carmel Pezaro, et al. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol 2017;71:970–8', European Urology, vol. 71, no. 6, pp. e177-e178. https://doi.org/10.1016/j.eururo.2016.12.013

Reply to Roberto Iacovelli, Walter Artibani, and Giampaolo Tortora's Letter to the Editor re : Ian D. Davis, Wanling Xie, Carmel Pezaro, et al. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol 2017;71:970–8. / Davis, Ian D.; Pezaro, Carmel; Xie, Wanling et al.

In: European Urology, Vol. 71, No. 6, 01.06.2017, p. e177-e178.

Research output: Contribution to journal › Letter › Other › peer-review

TY - JOUR

T1 - Reply to Roberto Iacovelli, Walter Artibani, and Giampaolo Tortora's Letter to the Editor re

T2 - Ian D. Davis, Wanling Xie, Carmel Pezaro, et al. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol 2017;71:970–8

AU - Davis, Ian D.

AU - Pezaro, Carmel

AU - Xie, Wanling

AU - Choueiri, Toni K.

AU - Heng, Daniel Y C

PY - 2017/6/1

Y1 - 2017/6/1

UR - http://www.scopus.com/inward/record.url?scp=85009412343&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2016.12.013

DO - 10.1016/j.eururo.2016.12.013

M3 - Letter

AN - SCOPUS:85009412343

VL - 71

SP - e177-e178

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 6

ER -

Davis ID, Pezaro C, Xie W, Choueiri TK, Heng DYC. Reply to Roberto Iacovelli, Walter Artibani, and Giampaolo Tortora's Letter to the Editor re: Ian D. Davis, Wanling Xie, Carmel Pezaro, et al. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol 2017;71:970–8. European Urology. 2017 Jun 1;71(6):e177-e178. https://doi.org/10.1016/j.eururo.2016.12.013

Access to Document

Other files and links

Research output

Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category

Cite this